By Counterforce Health Team in Besponsa (inotuzumab ozogamicin) —

How to Get Besponsa (Inotuzumab Ozogamicin) Covered by Cigna in Texas: Complete Appeals Guide with Forms and Timelines

Answer Box: Getting Besponsa Covered by Cigna in Texas

Cigna requires prior authorization for Besponsa (inotuzumab ozogamicin) with CD22-positive B-cell precursor ALL documentation. Submit the Cigna Besponsa CCRD PA form with pathology confirming CD22 status, relapsed/refractory disease history, and medical necessity letter. If denied, file internal appeal within 180 days, then Texas Independent Review Organization (IRO) external review within 4 months. Start today: Call your oncologist to request the PA form and gather CD22-positive pathology reports.

Table of Contents

  1. Understanding Cigna's Besponsa Prior Authorization
  2. Common Denial Reasons and How to Fix Them
  3. Step-by-Step: Fastest Path to Approval
  4. Medical Necessity Letter Template
  5. Texas Appeals Process: Internal to External Review
  6. Peer-to-Peer Call Strategy
  7. When Appeals Fail: Alternative Options
  8. Frequently Asked Questions

Understanding Cigna's Besponsa Prior Authorization

Besponsa (inotuzumab ozogamicin) is a specialty oncology drug that Cigna covers for adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL). However, prior authorization is mandatory across all Cigna plan types in Texas.

Coverage Requirements at a Glance

Requirement What It Means Where to Find It
Prior Authorization Required before first dose Cigna Besponsa CCRD Form
CD22-Positive Status Must document CD22 expression Flow cytometry/IHC report
Relapsed/Refractory Disease Failed prior ALL therapy Treatment history with dates
Hepatotoxicity Monitoring Baseline and ongoing LFTs Lab results and monitoring plan
Duration Limit Up to 6 cycles typically FDA labeling guidance

The key is understanding that Cigna uses specific clinical criteria. According to their Cancer Clinical Review Drug policy, you must answer "Yes" to both: "Does your patient have relapsed or refractory disease?" and "Is the patient's disease CD22-positive?"

Common Denial Reasons and How to Fix Them

Denial Reason How to Overturn Required Documents
CD22 status not documented Submit pathology/flow cytometry report Lab report showing CD22+ expression
Not relapsed/refractory Provide detailed treatment history Prior therapy dates, responses, failures
Missing hepatotoxicity plan Include monitoring protocol Baseline LFTs, ongoing monitoring schedule
Wrong line of therapy Clarify ALL subtype and prior treatments Oncology consult notes, treatment timeline
Dosing outside label Adjust to FDA-approved schedule Corrected prescription with proper dosing
Tip: The most common fixable issue is incomplete CD22 documentation. Ensure your pathology report explicitly states "CD22-positive" rather than just listing CD22 in a panel.

Step-by-Step: Fastest Path to Approval

1. Gather Required Documentation (Patient + Clinic)

  • Insurance card with Cigna ID and group number
  • Pathology report confirming CD22-positive B-cell precursor ALL
  • Complete treatment history with dates and outcomes
  • Current lab results (CBC, comprehensive metabolic panel)

2. Complete Cigna Besponsa CCRD Form (Prescriber)

Download the official PA form and complete all sections:

  • Patient identifiers and urgency level
  • Drug details with J-code and ICD-10
  • Clinical questions (relapsed/refractory: Yes, CD22-positive: Yes)
  • Free-text clinical information section

Timeline: Allow 2-3 business days for completion

3. Submit Prior Authorization (Clinic Staff)

  • Fax: 855-840-1678 (standard requests)
  • Phone: 800-882-4462 for urgent cases
  • Online: CoverMyMeds or Surescripts via EHR

Timeline: Cigna responds within 5 business days (standard), 72 hours (urgent)

4. Track Decision and Prepare for Potential Appeal

Monitor via Cigna provider portal or member services. If denied, immediately request the written denial letter with specific reasons.

Medical Necessity Letter Template

Here's a structured template your oncologist can adapt:

[Date]

To: Cigna Utilization Management
Re: Prior Authorization Request - Besponsa (inotuzumab ozogamicin)
Patient: [Name, DOB, Member ID]

Clinical Summary

Patient has CD22-positive B-cell precursor acute lymphoblastic leukemia, relapsed after [number] prior lines of therapy. CD22 expression confirmed by [flow cytometry/IHC] on [date].

Treatment History

  • First-line therapy: [regimen, dates, best response, reason for discontinuation]
  • Second-line therapy: [regimen, dates, response, failure reason]
  • Current status: Relapsed/refractory disease requiring salvage therapy

Medical Necessity Rationale

  1. Meets FDA indication: Adult with relapsed/refractory CD22+ B-cell precursor ALL
  2. Evidence-based choice: Phase 3 trial (Kantarjian 2017) showed superior outcomes vs. standard chemotherapy
  3. NCCN recommended: Listed as preferred option for this clinical scenario
  4. Bridge to transplant: Potential for achieving remission suitable for allogeneic HSCT

Hepatotoxicity Monitoring Plan

  • Baseline assessment: LFTs, coagulation studies completed
  • Ongoing monitoring: Weekly LFTs during treatment cycles
  • Risk mitigation: Limit to ≤6 cycles, coordinate with transplant team

Requested approval: Besponsa 0.9mg vials, up to 6 cycles per FDA labeling

Sincerely,
[Prescriber name, credentials, NPI]

Counterforce Health helps patients and clinicians turn insurance denials into successful appeals by analyzing denial letters, identifying the specific basis for rejection, and crafting targeted, evidence-backed rebuttals that align with each payer's own policies and procedures.

Texas Appeals Process: Internal to External Review

If Cigna denies your Besponsa prior authorization, Texas law provides a structured appeals pathway with specific deadlines.

Level 1: Internal Appeal

  • Deadline: 180 days from denial notice
  • How to file: Call 1-800-88-CIGNA or submit via member portal
  • Required documents:
    • Denial letter
    • Updated medical necessity letter
    • Additional clinical evidence
  • Timeline: 30 days (pre-service) or 60 days (post-service)
  • Expedited option: 72 hours if delay risks health

Level 2: Second Internal Appeal

  • Deadline: 60 days from Level 1 denial
  • Process: Different medical director reviews case
  • Timeline: 45-60 days for decision

External Review: Texas IRO Process

After exhausting internal appeals, Texas residents can request Independent Review Organization review:

  • Deadline: 4 months from final internal denial
  • Cost: Free to patient (Cigna pays IRO fees)
  • Timeline: 20 days standard, 72 hours expedited
  • Decision: Binding on Cigna
  • How to request: Call Texas Department of Insurance at 1-800-252-3439
Important: You can file a TDI complaint in parallel with your appeals. TDI recently fined Cigna $600,000 for compliance violations in Texas, so regulatory pressure can be effective.

Peer-to-Peer Call Strategy

If your initial PA is denied, request a peer-to-peer review before filing formal appeals.

Preparation Checklist

  • Cigna's exact denial reason and policy citation
  • Patient's complete treatment history with dates
  • CD22-positive pathology report
  • Current NCCN ALL guidelines (version and page)
  • Baseline hepatic function tests

Call Structure

  1. Opening: "I'm requesting coverage for Besponsa in a patient with CD22-positive relapsed B-cell precursor ALL who meets your published criteria."
  2. Address denial reason directly: If denied for insufficient documentation, provide specific lab values and dates. If denied for "not medically necessary," cite FDA indication and NCCN guidelines.
  3. Emphasize safety monitoring: "We have a comprehensive hepatotoxicity monitoring protocol including weekly LFTs and coordination with our transplant team."
  4. Propose compromise if needed: "We're willing to start with a 3-cycle approval with response assessment for continuation."

When working with Counterforce Health, many providers find that having a structured, policy-specific approach to peer-to-peer calls significantly improves approval rates compared to general medical necessity arguments.

When Appeals Fail: Alternative Options

Manufacturer Support Programs

  • Pfizer Oncology Together: Patient assistance and co-pay support
  • Eligibility: Varies by insurance type and income
  • Contact: PfizerOncologyTogether.com

Clinical Trial Options

  • Search ClinicalTrials.gov for inotuzumab ozogamicin studies
  • Consider combination trials with other agents
  • Expanded access programs may be available

Formulary Exception Process

If Besponsa is non-formulary on your specific Cigna plan:

  • Request formulary exception based on medical necessity
  • Provide evidence that formulary alternatives are inappropriate
  • May require step therapy documentation

Frequently Asked Questions

How long does Cigna prior authorization take for Besponsa in Texas?
Standard requests: 5 business days. Urgent requests (with clinical justification): 72 hours. Submit early to avoid treatment delays.

What if my Cigna plan is through Medicare Advantage?
Medicare Advantage plans follow similar PA requirements but have different appeal timelines (65 days for reconsideration). The same clinical criteria apply.

Can I get expedited review if I'm already in the hospital?
Yes. Mark requests "URGENT" and call 800-882-4462. Provide clinical rationale for why standard timeframes would jeopardize health.

Does step therapy apply to Besponsa?
Cigna's policy requires documentation of relapsed/refractory disease, which inherently means prior therapy failure. This satisfies step therapy requirements.

What if I've been on Besponsa before and need to restart?
Provide previous treatment dates, response achieved, reason for discontinuation, and current disease status. Retreatment may be covered if clinically appropriate.

How do I know if my appeal was successful?
Cigna will send written notification. Approvals include authorization number and approved duration. Track via member portal or call customer service.

What Texas resources can help with my appeal?
Contact Texas Department of Insurance (1-800-252-3439) for complaint assistance or Office of Public Insurance Counsel (1-877-611-6742) for consumer guidance.

Can my doctor prescribe a similar drug if Besponsa is denied?
Alternatives like blinatumomab may be options depending on your specific ALL subtype and prior treatments. Discuss with your oncology team.

Sources & Further Reading

Disclaimer: This information is for educational purposes and does not constitute medical or legal advice. Coverage decisions depend on individual plan terms and clinical circumstances. Always consult with your healthcare provider and insurance plan for specific guidance. For additional support with insurance appeals, contact the Texas Department of Insurance at 1-800-252-3439.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.